0001437749-20-013253.txt : 20200616
0001437749-20-013253.hdr.sgml : 20200616
20200616170713
ACCESSION NUMBER: 0001437749-20-013253
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200615
FILED AS OF DATE: 20200616
DATE AS OF CHANGE: 20200616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Voss Andreas
CENTRAL INDEX KEY: 0001661447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15911
FILM NUMBER: 20967186
MAIL ADDRESS:
STREET 1: C/O CELSION CORPORATION
STREET 2: 997 LENOX DRIVE, SUITE 100
CITY: LAWRENCEVILLE
STATE: NJ
ZIP: 08648
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celsion CORP
CENTRAL INDEX KEY: 0000749647
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 521256615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 997 LENOX DRIVE
STREET 2: SUITE 100
CITY: LAWRENCEVILLE
STATE: NJ
ZIP: 08648
BUSINESS PHONE: (609) 896-9100
MAIL ADDRESS:
STREET 1: 997 LENOX DRIVE
STREET 2: SUITE 100
CITY: LAWRENCEVILLE
STATE: NJ
ZIP: 08648
FORMER COMPANY:
FORMER CONFORMED NAME: CELSION CORP
DATE OF NAME CHANGE: 19980515
FORMER COMPANY:
FORMER CONFORMED NAME: CHEUNG LABORATORIES INC
DATE OF NAME CHANGE: 19920703
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-06-15
0000749647
Celsion CORP
CLSN
0001661447
Voss Andreas
C/O CELSION CORPORATION
997 LENOX DRIVE, SUITE 100
LAWRENCEVILLE
NJ
08648
1
Option to Purchase Celsion Corporation Common Stock
3.66
2020-06-15
4
A
0
4000
0
A
2021-06-15
2030-06-15
Celsion Corporation Common Stock
4000
111357
D
Option to Purchase Celsion Corporation Common Stock
2.22
2020-06-15
4
D
0
50000
0
D
2018-05-15
2028-05-15
Celsion Corporation Common Stock
50000
61357
D
Option to Purchase Celsion Corporation Common Stock
2.58
2020-06-15
4
A
0
50000
0
A
2018-05-15
2028-05-15
Celsion Corporation Common Stock
50000
111357
D
Represents the closing price of Celsion Corporation Common Stock on the date of grant.
The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant.
The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy).
/s/ Timothy J Tumminello, Controller and CAO
2020-06-16